Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Hematologic Malignancies”

706 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 706 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Testing effectiveness (Phase 2)UnknownNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)Study completedNCT00481871
What this trial is testing

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Who this might be right for
Relapsed or Refractory Lymphoproliferative MalignanciesHodgkin's LymphomaPeripheral T-cell Lymphoma+2 more
Acrotech Biopharma Inc. 119
Early research (Phase 1)Study completedNCT00019838
What this trial is testing

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Who this might be right for
LeukemiaLymphoma
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT04978779
What this trial is testing

Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Who this might be right for
Relapsed Non Hodgkin LymphomaChronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia+4 more
Vincerx Pharma, Inc. 6
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Testing effectiveness (Phase 2)Study completedNCT02639910
What this trial is testing

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
MorphoSys AG 24
Large-scale testing (Phase 3)UnknownNCT00003924
What this trial is testing

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Lymphoma Study Association 360
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Active Not RecruitingNCT02846623
What this trial is testing

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic Leukemia+2 more
M.D. Anderson Cancer Center 50
Very early researchLooking for participantsNCT04532203
What this trial is testing

CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma
Zhejiang University 72
Early research (Phase 1)Looking for participantsNCT06447987
What this trial is testing

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 24
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Early research (Phase 1)Ended earlyNCT02669264
What this trial is testing

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
ADC Therapeutics S.A. 35
Early research (Phase 1)Study completedNCT01290549
What this trial is testing

Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Who this might be right for
Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Genentech, Inc. 95
Very early researchLooking for participantsNCT04603872
What this trial is testing

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryAcute Lymphoblastic Leukemia, in Relapse+3 more
Zhejiang University 120
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Early research (Phase 1)Study completedNCT00923182
What this trial is testing

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Genzyme, a Sanofi Company 6
Load More Results